| http://www.w3.org/ns/prov#value | - Regulatory agencies, including the FDA, in fact persistently emphasize the need to collect sufficient clinical data on pharmacokinetics, concomitant medications, and comorbidities prior to Phase III. When this advice is not heeded, patients in the targeted therapeutic population may die from drug overdose, or may die from their disease because they are underdosed.
|
